Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

@article{Oshaughnessy2001RandomizedOP,
  title={Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.},
  author={J A Oshaughnessy and Joanne L. Blum and Vladimir M. Moiseyenko and Stephen E. Jones and David Miles and David Bell and Riccardo Rosso and Louis Mauriac and Bruno Osterwalder and Hans Ulrich Burger and Simon Laws},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2001},
  volume={12 9},
  pages={1247-54}
}
BACKGROUND Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer. PATIENTS AND METHODS Ninety-five patients were randomized (2:1) to either intermittent oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period) or intravenous CMF (cyclophosphamide. methotrexate, 5-fluorouracil [5-FU]) administered every three weeks… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
94 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 94 extracted citations

Similar Papers

Loading similar papers…